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ductal carcinomas in situ. Axillary lymph node involvement 
was seen in 34.3%. Most of the tumors were estrogen positive 
(68.75%) and progesterone positive (65.6%). A systemic 
therapy was given in 81.25% of the patients. After second 
breast conserving therapy or no surgery re- RT was given to 
the involved quadrant using external- beam ports (electrons 
or photons) with doses of 50-60Gy in 2Gy per fraction. The 
median age at local relapse was 65.8 years. A second breast 
conserving therapy was performed in 90.7% of the women, 
9.3% had no surgery and were re-irradiated to a dose of 
60Gy. A systemic therapy was given in 84.3%.Survival and 
local control were calculated by the Kaplan-Meier actuarial 
method. 
 
Results: A total of 32 patients were retrospectively analyzed. 
The median follow up of survivors was 181 months from first 
diagnosis and 33 month from second RT. At the time of 
analysis 4 patients had died. The median time between first 
and second RT was 9.9 years (range 1.8- 20.3). Fifteen years 
after first diagnosis 86% of the patients were still alive. Four 
women died, 3 on cancer. After second RT only one acute G2 
toxicity of the skin was reported (desquamation).Late 
toxicity was scored using the LENT- SOMA Score Criteria. 
Lymphedema (G1) of the ipsilateral arm was observed in 
3.1%, 3.1% reported on intermittent pain in the breast and 
9.3% presented with an asymptomatic breast edema. The 
highest rate of late toxicity was G2 fibrosis in 18.7%.No G3 or 
G4 toxicity was observed.  
 
Conclusion: Carefully planned re-RT of the involved breast 
quadrant is a safe alternative therapy for those women who 
did not gave their consent to the recommended mastectomy. 
No second local relapse was detected after re-RT. Acute side 
effects were low. In 18.7% of the women fibrosis G2 was 
detected. 
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Purpose or Objective: Cancer en cuirasse is a severe 
locoregional manifestation of breast cancer, usually occurring 
after a number of treatment failures. Treatment options are 
limited. One hundred and sixty-nine patients were treated 
with re-irradiation and hyperthermia (reRT+HT) from 1982 till 
2006. Response and toxicity rates as well as the locoregional 
progression free interval were determined to assess the 
palliative value of this treatment. 
 
Material and Methods: All patients had received extensive 
previous treatments, including surgery, irradiation (median 
dose 50Gy with or without boost) and systemic treatments.. 
Seventy-five percent of patients had 1-7 previous 
locoregional recurrence episodes; 68% were treated with 
systemic therapies and 27% underwent salvage surgery.  
At start of re-RT+HT the tumor area comprised > 3/4 
ipsilateral chest wall in 54% of patients. Fifty-two percent 
had areas of ulcerating tumor. Distant metastases were 
present in 45% of patients. reRT consisted typically of 8x4Gy, 
twice a week or 12x3Gy, four times a week. Superficial 
hyperthermia was applied once or twice a week using 434MHz 
Contact Flexible Microstrip Applicators (CMFA), heating the 
tumor area to 41-43˚C for one hour. 
 
Results: The treatment was well tolerated; 154 patients 
completed treatment, only 15 patients did not, due to 
disease progression in 12, toxicity in 2 and refusal in 1 
patient. Overall clinical response rate was 72% (30% CR; 42% 
PR), while only 6% showed PD. Median follow-up time was 7 
months. The 1-year progression-free-interval was 24% with a 
1-year survival rate of 36%. Acute ≥ grade 3 toxicity occurred 
in 33% of patients and consisted mostly of ulceration and 
dermatitis. The occurrence of radiation ulcera was 
significantly related to the presence of ulcerating tumor 
before the start of the reRT-HT (P=0.004, HR = 4.4). 
 
Conclusion: The combination of re-irradiation and 
hyperthermia is well tolerated and results in high response 
rates despite extensive disease and resistance to previous 
treatments. ReRT+HT is a worthwhile palliative treatment 
option for this patient group who suffer from extensive 
locoregional tumor growth and have a very poor prognosis.  
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Purpose or Objective: Stereotactic radiotherapy (SRT) of 
brain metastases results in regression of most treated 
metastases, but subsequent lesion growth may occur and is 
caused by either tumor progression or pseudo-progression, 
which is probably a radiation effect on surrounding normal 
brain tissue. It is unknown if active treatment is indicated in 
symptomatic patients, or if it is better to wait for 
spontaneous recovery. The purpose of this study is to 
describe the clinical course of brain metastasis patients 
developing pseudo-progression after SRT to improve clinical 
decision-making. 
 
Material and Methods: Follow-up MRI scans of all patients 
who received SRT of brain metastases from 2009 through 
2012 were reviewed for post SRT lesion growth. Depending on 
the volume of the metastasis, the patients had received one 
fraction of 21Gy, 18Gy, or 15Gy, or three fractions of 8Gy or 
8.5Gy. The GTV-PTV margin was 2mm. Pseudo-progression 
was considered to be the cause of this lesion growth if a 
histological diagnosis of necrosis had become available, if the 
lesion had shown subsequent regression or if two neuro-
radiologists agreed upon this diagnosis based on a review of 
the follow-up perfusion MRI scans. The clinical course of the 
patients with these pseudo-progressive lesions was 
retrospectively studied. 
 
Results: In a total of 237 treated patients we identified 37 
patients with 50 pseudo-progressive lesions. The median 
follow-up of all patients still alive was 40.7 months. The main 
clinical symptoms that were attributed to this lesion growth 
were neurologic deficits, headache and seizures in 19 (51%), 
3 (8%) and 4 (11%) patients respectively (unknown in one). 
Ten patients (27%) had no symptoms attributed to the lesion 
growth and remained asymptomatic afterwards. Of the 19 
patients with neurologic deficits one improved after 
spontaneous regression of the lesion, one improved after 
surgery and 17 did not improve. Two out of the four patients 
with seizures improved with ant-epileptic drugs (AED’s), one 
improved after surgery and one did not improve. Only one of 
the three patients with headache improved with steroids. 
Spontaneous regression of an initially pseudo-progressive 
lesion was observed in 18 patients. Twelve of these 18 
patients had symptomatic pseudo-progression, but only one 
of these 12 patients experienced neurologic improvement 
without treatment. In 6 patients their deaths were related to 
the pseudo-progressive lesion.  
 
Conclusion: Patients with an asymptomatic pseudo-
progressive lesion frequently remain asymptomatic. Patients 
with a symptomatic pseudo-progressive lesion only rarely 
recover spontaneously. Active treatment, such as surgery, 
should be considered for these patients. Therefore, 
